CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-07 | Sohn Catherine A. Director | Option exercise · Stock Option (Right to Buy) | −20,744 | 0 | ||
| 2026-01-07 | Sohn Catherine A. Director | Option exercise · Stock Option (Right to Buy) | −2,895 | 316 | ||
| 2026-01-07 | Sohn Catherine A. Director | Option exercise · Stock Option (Right to Buy) | −3,281 | 5,805 | ||
| 2026-01-06 | Sohn Catherine A. Director | Option exercise | +2,493 | $10.42 | $26K | 2,493 |
| 2026-01-06 | Sohn Catherine A. Director | Sale | −2,493 | $38.62 | $96K | 0 |
| 2026-01-06 | Sohn Catherine A. Director | Option exercise · Stock Option (Right to Buy) | −2,493 | 3,211 | ||
| 2026-01-05 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +412 | $10.42 | $4K | 412 |
| 2026-01-05 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −412 | $40.00 | $16K | 0 |
| 2026-01-05 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −412 | 337,563 | ||
| 2026-01-02 | Bachrodt Amy SVP, Finance | Option exercise 10b5-1 | +204 | $10.42 | $2K | 13,169 |
| 2026-01-02 | Bachrodt Amy SVP, Finance | Option exercise 10b5-1 | +4,796 | $10.42 | $50K | 17,965 |
| 2026-01-02 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −2,405 | $38.70 | $93K | 15,560 |
| 2026-01-02 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −2,595 | $39.57 | $103K | 12,965 |
| 2026-01-02 | Bachrodt Amy SVP, Finance | Option exercise · Stock Option (Right to Buy) 10b5-1 | −204 | 2,377 | ||
| 2026-01-02 | Bachrodt Amy SVP, Finance | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,796 | 2,983 | ||
| 2026-01-02 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +4,432 | $10.42 | $46K | 4,432 |
| 2026-01-02 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −4,432 | $40.43 | $179K | 0 |
| 2026-01-02 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,432 | 337,975 | ||
| 2025-12-30 | Bachrodt Amy SVP, Finance | Option exercise 10b5-1 | +2,395 | $10.42 | $25K | 15,360 |
| 2025-12-30 | Bachrodt Amy SVP, Finance | Option exercise 10b5-1 | +2,605 | $10.42 | $27K | 17,965 |
Page 10 of 14 · 267 trades